Ion Beam Applications SA (OTCPK:IOBCF) Q2 2025 Earnings Call August 28, 2025 9:00 AM ET
Company Participants
Catherine Vandenborre – Chief Financial Officer & Corporate Lead
Henri de Romree – Deputy CEO, Internal Director & Managing Director
Olivier Legrain – CEO, MD & Executive Director
Thomas Pevenage – Corporate Participant
Conference Call Participants
David Vagman – ING Groep N.V., Research Division
Laura Roba – Banque Degroof Petercam S.A., Research Division
Michiel Declercq – KBC Securities NV, Research Division
Thomas Pevenage
Hello, everyone, and welcome to the presentation of IBA’s results for the first half of 2025. I am Thomas Pevenage, Head of Investor Relations. As usual, you will find this presentation on the Investor Relations page of our website. A question-and-answer session will follow the formal presentation.
Moving to the next page, let me draw your attention to the company’s disclaimer for forward-looking statements, which, as you know, are based on our current assumptions and beliefs and subject to risks and uncertainties. Today’s speakers are Olivier Legrain, our Chief Executive Officer and IBA Clinical Lead; Henri de Romree, our Deputy Chief Executive Officer and IBA Technologies Lead, and we are pleased to welcome Catherine Vandenborre, our newly appointed Chief Financial Officer and IBA Corporate Leads.
As you know, Catherine joined us on the 1st of July. Please note the agenda for today’s presentation. We’ll start with our highlights for the period, followed by a business review where we will discuss the strategic progress and the financials of each business unit. And finally, we’ll cover our financial performance in more detail and give you an update on our guidance and outlook.
Olivier Legrain
Thank you very much, Thomas. Good afternoon, everybody. We are happy to share our achievement with all of you today. We are proud to announce a strong first half of the year, underpinned by
